| Epigenomic signatures of sarcomatoid differentiation to guide the treatment of renal cell carcinoma T El Zarif, K Semaan, M Eid, JH Seo, S Garinet, MP Davidsohn, P Sahgal, ... Cell Reports 43 (6), 2024 | | 2024 |
| Detecting small cell transformation in patients with advanced EGFR mutant lung adenocarcinoma through epigenomic cfDNA profiling T El Zarif, CB Meador, X Qiu, JH Seo, MP Davidsohn, H Savignano, ... Clinical Cancer Research, 2024 | | 2024 |
| Correlation of circulating tumor DNA (ctDNA) dynamics with clinical response in patients with muscle-invasive bladder cancer (MIBC) undergoing trimodality therapy (TMT). IB Epstein, SA Berg, C Mantia, M Mossanen, A Saraf, MA Preston, A Ravi, ... Journal of Clinical Oncology 42 (16_suppl), e16606-e16606, 2024 | | 2024 |
| Methods and compositions for identifying neuroendocrine prostate cancer J Berchuck, M Freedman, S Baca US Patent App. 18/272,184, 2024 | | 2024 |
| Characterising the contribution of rare protein-coding germline variants to prostate cancer risk and severity in 37,184 cases J Mitchell, N Camacho, P Shea, KH Stopsack, V Joseph, O Burren, ... medRxiv, 2024 | | 2024 |
| A Panel-Based Mutational Signature of Mismatch Repair Deficiency is Associated With Durable Response to Pembrolizumab in Metastatic Castration-Resistant Prostate Cancer D Boiarsky, DC Gulhan, H Savignano, G Lakshminarayanan, HM McClure, ... Clinical Genitourinary Cancer 22 (2), 558-568. e3, 2024 | | 2024 |
| Author Correction: Liquid biopsy epigenomic profiling for cancer subtyping SC Baca, JH Seo, MP Davidsohn, B Fortunato, K Semaan, S Sotudian, ... nature medicine 30 (3), 907-907, 2024 | | 2024 |
| Detection of sarcomatoid renal cell carcinoma using plasma cell-free DNA methylation. K Semaan, T El Zarif, JH Seo, M Eid, J Canniff, B Fortunato, H Savignano, ... Journal of Clinical Oncology 42 (4_suppl), 449-449, 2024 | | 2024 |
| Detection of neuroendocrine prostate cancer through plasma-based epigenomic profiling. M Eid, K Semaan, JH Seo, MP Davidsohn, B Fortunato, ... Journal of Clinical Oncology 42 (4_suppl), 201-201, 2024 | | 2024 |
| Comprehensive multiplexed autoantibody profiling of patients with advanced urothelial cancer P Ravi, D Freeman, J Thomas, A Ravi, C Mantia, BA McGregor, ... Journal for Immunotherapy of Cancer 12 (2), 2024 | | 2024 |
| The Double Antibody Drug Conjugate (DAD) phase I trial: sacituzumab govitecan plus enfortumab vedotin for metastatic urothelial carcinoma BA McGregor, GP Sonpavde, L Kwak, MM Regan, X Gao, H Hvidsten, ... Annals of Oncology 35 (1), 91-97, 2024 | 17 | 2024 |
| Co-occurring BRCA2/SPOP mutations predict exceptional poly (ADP-ribose) polymerase inhibitor sensitivity in metastatic castration-resistant prostate cancer JJ Orme, F Taza, N De Sarkar, AK Tewari, SA Naqvi, IB Riaz, DS Childs, ... European Urology Oncology, 2023 | 1 | 2023 |
| Liquid biopsy epigenomic profiling for cancer subtyping SC Baca, JH Seo, MP Davidsohn, B Fortunato, K Semaan, S Sotudian, ... Nature medicine 29 (11), 2737-2741, 2023 | 24 | 2023 |
| 2360O The double antibody drug conjugate (DAD) phase I trial: Sacituzumab govitecan (SG) plus enfortumab vedotin (EV) as≥ second-line therapy for metastatic urothelial … BA McGregor, GP Sonpavde, L Kwak, X Gao, C Mantia, XX Wei, ... Annals of Oncology 34, S1199-S1200, 2023 | 2 | 2023 |
| 1206O Clinical subtyping of cancer from blood based on comprehensive epigenomic profiling S Baca, JH Seo, JE Berchuck, T El Zarif, RM Saliby, K Semaan, ... Annals of Oncology 34, S711, 2023 | | 2023 |
| Epigenomic profiling nominates master transcription factors (TFs) driving sarcomatoid differentiation (SD) of renal cell carcinoma (RCC). TE Zarif, K Semaan, M Eid, B Fortunato, AH Nassar, SA Alaiwi, Z Bakouny, ... Oncologist 28, 2023 | | 2023 |
| Epigenomic profiling nominates master transcription factors (TFs) driving sarcomatoid differentiation of renal cell carcinoma (RCC) K Semaan, T El Zarif, M Eid, V Shah, B Fortunato, RM Saliby, AH Nassar, ... CANCER RESEARCH 83 (16), 2023 | | 2023 |
| Abstract A029: Epigenomic profiling nominates master transcription factors (TFs) driving sarcomatoid differentiation of renal cell carcinoma (RCC) K Semaan, TE Zarif, M Eid, V Shah, B Fortunato, RM Saliby, AH Nassar, ... Cancer Research 83 (16_Supplement), A029-A029, 2023 | | 2023 |
| Nucleosome patterns in circulating tumor DNA reveal transcriptional regulation of advanced prostate cancer phenotypes N De Sarkar, RD Patton, AL Doebley, B Hanratty, M Adil, AJ Kreitzman, ... Cancer discovery 13 (3), 632-653, 2023 | 21 | 2023 |
| Differential responses to taxanes and PARP inhibitors in ATM‐ versus BRCA2‐mutated metastatic castrate‐resistant prostate cancer CT Su, E Nizialek, JE Berchuck, PJ Vlachostergios, R Ashkar, A Sokolova, ... The Prostate 83 (3), 227-236, 2023 | 5 | 2023 |
